Back

Relative bioavailability and pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet oral formulation and the effect of food and gender in healthy human subjects

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pulmonary hypertension: progress in management, impact on outcomes Pulmonary Hypertension ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor John Adams

Arena Pharmaceuticals, San Diego (United States of America)

9 More presentations in this session

Presentation thumbnail
Fast screening breath analysis for diagnostics of pulmonary hypertension.
Assistant Professor A. Swinarew (Katowice, PL)
Abstract Slides Video
Presentation thumbnail
Phenomapping to detect non-invasively patients with combined postcapillary pulmonary hypertension
Doctor O. Raitiere (Le Havre Cedex, FR)
Abstract Slides Video
Presentation thumbnail
Impact of comorbidity on outcome in CTD-associated pulmonary arterial hypertension: data from the Swedish Pulmonary Arterial Hypertension Registry
Doctor C. Hjalmarsson (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension
Professor N. Galie (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Improved ten-year survival of systemic sclerosis-associated pulmonary arterial hypertension in the contemporary treatment era: a single centre retrospective study of 451 patients.
Doctor H. Fayed (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension: progress in management, impact on outcomes

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources